S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

$48.65
+0.65 (+1.35%)
(As of 01:44 PM ET)
Compare
Today's Range
$47.44
$48.66
50-Day Range
$37.29
$48.00
52-Week Range
$22.31
$52.23
Volume
39,294 shs
Average Volume
90,219 shs
Market Capitalization
$874.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.67

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.0% Upside
$55.67 Price Target
Short Interest
Healthy
1.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
1.03mentions of ANI Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
37.11%
From $2.56 to $3.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

66th out of 980 stocks

Pharmaceutical Preparations Industry

26th out of 485 stocks


ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
ANI Pharmaceuticals Drops 10% After Pricing Share Offering
ANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $59.00
Q1 2023 ANI Pharmaceuticals Inc Earnings Call
Why ANI Pharmaceuticals Stock Is Soaring Today
See More Headlines

ANIP Price History

ANIP Company Calendar

Last Earnings
3/09/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.67
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+16.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,900,000.00
Pretax Margin
-9.65%

Debt

Sales & Book Value

Annual Sales
$316.39 million
Cash Flow
$4.04 per share
Book Value
$17.50 per share

Miscellaneous

Free Float
12,851,000
Market Cap
$862.56 million
Optionable
Optionable
Beta
1.02

Key Executives

  • Nikhil LalwaniNikhil Lalwani
    President, Chief Executive Officer & Director
  • James G. Marken
    Senior VP-Operations & Product Development
  • Stephen P. CareyStephen P. Carey
    Chief Financial Officer & Senior VP-Finance
  • Muthusamy Shanmugam
    Director & Head-Research & Development
  • Mary Pao
    Chief Medical Officer













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their ANIP share price forecasts range from $48.00 to $60.00. On average, they anticipate the company's share price to reach $55.67 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of the year. Since then, ANIP stock has increased by 19.3% and is now trading at $48.00.
View the best growth stocks for 2023 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 336,900 shares, a decline of 15.9% from the April 30th total of 400,700 shares. Based on an average daily volume of 104,000 shares, the days-to-cover ratio is presently 3.2 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, March, 9th. The specialty pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.10. The specialty pharmaceutical company had revenue of $94.23 million for the quarter, compared to analysts' expectations of $86.76 million. ANI Pharmaceuticals had a negative net margin of 7.34% and a positive trailing twelve-month return on equity of 10.60%.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of $2.99-$3.45 for the period, compared to the consensus EPS estimate of $2.43. The company issued revenue guidance of $385.00 million-$410.00 million, compared to the consensus revenue estimate of $361.82 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.10%), Rubric Capital Management LP (3.61%), Dimensional Fund Advisors LP (3.04%), William Blair Investment Management LLC (3.02%), Global Alpha Capital Management Ltd. (2.65%) and State Street Corp (2.56%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $48.00.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $862.56 million and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 601 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -